Founded in 2009, Mitra Biotech Pvt. Ltd., focuses on enabling personalized cancer care and rational drug development. Mitra is led by an accomplished team of diagnostic and drug development professionals and is backed by world's leading venture groups. The company's technology enables physicians to make an informed treatment decision for a cancer patient by determining optimal drug combination; and rational drug development by identifying driver pathways/mutations. It offers CANScript, a multidimensional laboratory-based screening platform that enables physicians to select the optimal drug combination for a cancer patient.